The pregnancy specific beta-1-glycoprotein (SP1) was measured by radioimmunoassay in 854 persons (control group 103, non-tumoral diseases 212, germinal tumors 30, and non-germinal tumors 509). Amounts higher than 2.5 ng/ml (upper normal limit) were observed in 35 cases with non tumoral diseases (specially chronic liver diseases), 97 of the non-germinal tumors (specially mammary, respiratory and digestive tumors), and 10 of the germinal tumors (pure and mixed choriocarcinomas, and embryonic carcinoma with yolk sac component). SP1 rarely is higher than 5 ng/ml in non-tumoral diseases and non-germinal tumors, while it is higher than 5 ng/ml in germinal tumors. SP1 is a good marker for trophoblastic neoplasms and shows a correlation with HCG-beta.

Age Factors↗

PubMed1984

CA125 seric levels in non malignant pathologies.

Explore the source record for details and available documents.

Adolescent↗

PubMed1984

[Serum beta 2 microglobulin in patients with solid tumors and tumors of the hematopoietic system].

In order to know the usefulness of beta-2-microglubulin as a tumor marker, the authors measured by radioimmunoassay its serum concentration in 222 patients with solid tumors of different localization. 116 patients with hematologic neoplasms, and 254 cases grouping healthy individuals and patients with diseases other than cancer. The upper limit of normality was considered as 3 micrograms/ml; 35.6 per 100 of the investigated solid tumors and 43.8 per 100 of the blood-forming organs neoplasms gave values higher than 3 micrograms/ml, against only 5 and 10 per 100 of the healthy and non-cancer patients respectively used as a control. Many cancer patients did not show an augmentation of beta-2-microglobulin. The authors consider that beta-2-microglobulin does not offer enough sensitivity and specificity to be used as a tumor marker.

Humans↗

PubMed1984

[Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].

In order to know the behavior of the tissue polypeptide antigen (TPA) as a tumor marker, the authors determine its amount in serum by means of radioimmunoassay (TPA Prolifigen RIA) in 441 patients having respiratory, digestive, urogenital, hematopoietic, mammary and other malignant tumors. The obtained results indicate that: TPA has no tumor specificity; however it increases in tumors without any other known tumor marker. TPA has no diagnostic value, but it is useful for the following up of digestive, mammary, respiratory, ovarian and testicular cancer; amounts of TPA comprised between 90 and 120 U/l are not specific and have no clinical significance; and it is very useful the simultaneous determination of CEA and TPA in the respiratory, digestive and mammary malignant neoplasms to help the clinical data in the evaluation of tumor mass (CEA) and tumor activity (TPA) without indication of tumor localization.

Adult↗

PubMed1984

[Tissue polypeptide antigen (TPA) in non-neoplastic diseases].

Radioimmunoassay (TPA Prolifigen RIA) was used to determine the serum concentration of TPA in 333 patients with different kinds of non-tumoral diseases. Amounts higher than 90 U/l, that was taken as the upper normal limit, were observed in 40 per 100 of the cases, being higher than 200 U/l in 10 per 100. The frequency of abnormal amounts of TPA in non-tumoral diseases obliges to eliminate them before making a diagnosis of cancer.

Antigens, Neoplasm↗

PubMed1983